C.A. Thomas
New England Cancer Specialists · 11 works · 131 citations · h-index 6
Top works
- Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
- Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
- Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK
- 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
- 134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
- P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab
- Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK
- IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)
- 258eP Effective biomarker testing rates in advanced non-small cell lung cancer (NSCLC) patients in U.S. community oncology practices